Leber congenital amaurosis 7 is a rare genetic eye condition that causes severe vision loss from birth or early infancy. Many people with Leber congenital amaurosis 7 have very poor night vision, light sensitivity, and fast back-and-forth eye movements. Vision problems are lifelong, and some may notice slow changes over time. It mainly affects babies and young children, and family history can be a clue. Treatment focuses on low-vision aids, orientation and mobility training, and supportive therapies, and most children grow and live into adulthood with appropriate care.
Overview
Leber congenital amaurosis 7Symptoms
Leber congenital amaurosis 7 is typically recognized in early infancy with severe vision loss, eye shaking (nystagmus), poor light response, and light sensitivity. Early signs of Leber congenital amaurosis 7 include eye‑rubbing or pressing and marked farsightedness.
Outlook and prognosis
Many living with Leber congenital amaurosis 7 (LCA7) notice vision problems from infancy that usually remain severe throughout life. Sight often stays stable or slowly worsens, with night and peripheral vision commonly affected. Regular low-vision care, protective eyewear, and emerging trials support daily independence.
Causes and risk factors
Leber congenital amaurosis 7 results from changes in the CRX gene, typically autosomal dominant. An affected parent has a 50% chance of passing it on; some cases are new mutations. Environment or lifestyle don’t cause it, but may affect complications.
Genetic influences
Genetics are central to Leber congenital amaurosis 7; it’s caused by inherited changes in the gene usually passed in an autosomal recessive pattern. Variants influence severity, age at diagnosis, and response to emerging gene-specific therapies. Genetic testing guides care and family planning.
Diagnosis
Diagnosis relies on early-onset vision problems, nystagmus, and absent or markedly reduced electroretinography. Retinal imaging helps show characteristic changes. Genetic diagnosis of Leber congenital amaurosis 7 is confirmed by multigene panel or targeted testing.
Treatment and drugs
Treatment for Leber congenital amaurosis 7 focuses on vision support, protecting remaining sight, and addressing day‑to‑day needs. Care may include low‑vision aids, orientation and mobility training, tinted lenses, and treating nystagmus or refractive error. Regular follow‑up with inherited retina specialists and genetic counseling helps plan care and discuss trial options.
Symptoms
From the first months of life, families often notice vision doesn’t develop as expected—little eye contact, poor tracking, or reaching by touch rather than sight. These early features of Leber congenital amaurosis 7 reflect reduced function of the retina’s light-sensing cells. Features vary from person to person and can change over time. Everyday life is shaped by reduced vision, but support, low-vision tools, and early therapies can help babies and children engage and learn.
From birth or the first months, babies may show limited visual response. They may not track faces or reach toward toys by sight. This reduced vision is a core feature of Leber congenital amaurosis 7.
Nystagmus (shaky eye movements) often appears in infancy. You may notice the eyes move side to side or “search” when trying to focus. This is common in Leber congenital amaurosis 7.
The pupils may react weakly or slowly to light. Doctors often see less pupil “dimming” in bright light during exams. This doesn’t always reflect how the child uses vision in daily settings.
Seeing in dim rooms or at dusk can be especially hard. Children may move closer to lights or prefer brighter areas to make out shapes. For some with Leber congenital amaurosis 7, this remains a consistent challenge.
How people usually first notice Leber congenital amaurosis 7?
Parents and doctors often notice the first signs of Leber congenital amaurosis 7 (LCA7) in infancy, when a baby doesn’t track faces or toys, shows poor visual alertness, or has rapid, shaky eye movements called nystagmus. Some babies press or rub their eyes vigorously (oculodigital sign) or seem very sensitive to light, prompting an early eye exam. In many cases, how LCA7 is first noticed is through a pediatric or ophthalmology check that finds very poor visual responses and an abnormal electroretinogram (ERG), which measures how the retina reacts to light.
Types of Leber congenital amaurosis 7
Leber congenital amaurosis 7 (LCA7) is a genetic eye condition linked to changes in the CRX gene. Variants of LCA7 are defined by the specific CRX mutation and how strongly it disrupts the gene’s “dimmer switch” role in turning on light-sensing genes in the retina. This leads to a spectrum that ranges from severe, early-onset vision loss to milder, later-onset disease. Not everyone will experience every type.
Classic early-onset
Severe CRX loss-of-function causes profound vision problems in infancy with poor or absent light response. Nystagmus and very reduced visual acuity are common, and doctors often see markedly reduced electrical signals on eye testing. This represents the most typical early symptoms of LCA7.
Dominant retinitis pigmentosa
Some CRX mutations act in a dominant-negative way and present later as retinitis pigmentosa. Night blindness and side vision loss start in childhood or adulthood, with central vision declining over time. Clinicians often describe them in these categories: early-onset LCA-like versus later-onset RP-like presentations.
Cone-rod dystrophy
Certain variants mainly affect cone cells first, leading to early problems with reading vision, color, and light sensitivity. Rod-related night vision issues follow later. Visual acuity may decline from school age into adulthood.
Milder hypomorphic variant
Partially working CRX changes may cause a slower, milder course with usable vision into adolescence or adulthood. People may notice light sensitivity and gradual blurring rather than profound early loss. The balance of symptoms can shift over time.
Maculopathy-predominant
A subset shows changes centered in the macula, the sharp-seeing area, causing central blur and difficulty with fine detail. Side vision and night vision can be relatively preserved early on. Progression varies with the specific CRX mutation.
What genetics can tell you about symptoms
In Leber congenital amaurosis 7, variations in the gene often disrupt photoreceptor function, leading to severe vision loss or blindness in infancy. Some people also experience light sensitivity, wandering eye movements, or markedly reduced night vision tied to how strongly the variant affects retinal cells.
Causes and risk factors
Harmful changes in the CRX gene, which helps the retina form and work, cause Leber congenital amaurosis 7.
These changes are often inherited in a dominant pattern, and sometimes arise as a new change with no family history.
Some risks are written in our DNA, passed down through families.
There are no known environmental or lifestyle causes, and everyday habits do not trigger LCA7.
Family history can hint at the early symptoms of Leber congenital amaurosis 7, but severity can still vary.
Environmental and biological risk factors
Leber congenital amaurosis 7 is present from birth, so risk relates to events before conception and in very early development. People often search for early symptoms of Leber congenital amaurosis 7, but here we focus on what can raise or lower the chance of it occurring in the first place. Awareness of both biological and environmental influences helps you feel prepared. Most factors below have small effects on their own, but knowing them can guide planning and questions during prenatal or preconception care.
As people get older, sperm accumulate more new changes in DNA, which can raise the chance of a rare single-gene condition starting in a child. The effect grows with age but remains small for any single pregnancy.
Egg quality and DNA repair change over time and can slightly increase the chance of new DNA changes in a baby. This maternal-age effect is generally smaller for single-gene conditions than the paternal effect.
Sometimes a one-time change arises in the egg, sperm, or early embryo by chance. This can lead to Leber congenital amaurosis 7 even when it appears unexpectedly. The overall likelihood for any given pregnancy remains low.
High-dose radiation to a parent’s reproductive organs before conception can increase DNA damage in eggs or sperm. This may raise the chance of rare conditions that begin from new gene changes. Medical imaging typically uses much lower doses than cancer radiotherapy.
Genetic risk factors
In Leber congenital amaurosis 7 (LCA7), changes in the CRX gene are the main driver. If you’re exploring the genetic causes of Leber congenital amaurosis 7, most confirmed cases trace back to a single altered copy of CRX. People with the same risk factor can have very different experiences. Some families show the condition across generations, while others have a single affected child due to a new, spontaneous change.
CRX gene variants: Changes in the CRX gene disrupt steps that photoreceptor cells need to form and work. This is the main cause of Leber congenital amaurosis 7. Most changes are small alterations in the DNA code.
Autosomal dominant: One altered CRX copy is enough to cause LCA7. Each child of an affected parent has about a 50% chance to inherit the change.
De novo variants: Some CRX changes occur for the first time in a child with LCA7. Parents may have normal testing, and the chance of it happening again is usually low but not zero.
Parental mosaicism: A parent can carry the CRX change in some egg or sperm cells but not in blood. This mosaic pattern can slightly raise the recurrence risk for another child with Leber congenital amaurosis 7.
Variable expressivity: The same CRX variant can cause different levels of vision loss and different ages of onset. In some families, one relative has severe early LCA7 while another has milder, later vision problems.
Phenotypic overlap: CRX variants can also be linked with cone-rod dystrophy or retinitis pigmentosa. This overlap means family histories may include different retinal diagnoses even when the genetic risk is the same.
Copy-number changes: Rare deletions or duplications involving CRX can lead to LCA7. These larger changes may require special testing methods to detect.
Lifestyle risk factors
Lifestyle habits do not cause Leber congenital amaurosis 7, but they can influence day-to-day vision comfort, safety, and quality of life. Understanding how lifestyle affects Leber congenital amaurosis 7 can help reduce strain on the eyes and prevent avoidable complications like falls or headaches. The points below focus on practical habits that directly impact visual function, comfort, and independence in LCA7.
Tobacco smoke increases oxidative stress on retinal cells and may accelerate loss of remaining visual function. Quitting can help preserve residual vision and lower cataract risk.
UV-blocking sunglasses and brimmed hats reduce phototoxic stress on the retina and ease photophobia. Consistent glare control can decrease eye strain and headache frequency.
High-contrast materials, large print, and magnification reduce visual effort for reading and mobility. Limiting prolonged screen glare and taking regular breaks may lessen eye fatigue, even if they do not change retinal degeneration.
A balanced diet with leafy greens and omega-3–rich foods supports retinal metabolism and overall eye health. Avoid high-dose vitamin A or unproven supplements unless a specialist advises, as benefits in LCA7 are uncertain and risks exist.
Risk prevention
Leber congenital amaurosis 7 is inherited, so you can’t prevent the condition itself. The goal is to lower risks of complications, support vision and development, and plan family options with good information. Prevention works best when combined with regular check-ups. Knowing early symptoms of Leber congenital amaurosis 7 and getting a prompt diagnosis can help you act sooner on supports that protect long‑term function.
A genetics visit can confirm the exact subtype of Leber congenital amaurosis 7 and explain inheritance. It also covers partner testing and options like prenatal or preimplantation genetic testing for future pregnancies.
Regular visits with a pediatric eye specialist help track eye growth, glasses needs, and retinal health. Early follow-up lowers the chance of missing treatable issues that can add to vision loss.
Frequent rubbing can raise the risk of keratoconus (a cone-shaped cornea) and worsen vision. Treating itchy eyes and allergies, using cold compresses, and offering gentle reminders can reduce rubbing.
Correcting farsightedness or nearsightedness with glasses or contacts supports the best possible vision. Treating amblyopia or eye misalignment early may preserve function that would otherwise be lost.
Transmission
Leber congenital amaurosis 7 is not contagious; it can’t be caught, and it isn’t spread by coughing, touch, or everyday contact. It happens because of a change in a gene important for vision.
The genetic transmission of Leber congenital amaurosis 7 is usually autosomal dominant, meaning one altered copy from an affected parent is enough to cause the condition, and each child has a 1 in 2 (50%) chance of inheriting it. Sometimes it appears for the first time in a family due to a new genetic change, so there may be no prior family history; a genetics professional can help explain how Leber congenital amaurosis 7 is inherited in your situation.
When to test your genes
Consider genetic testing if you or a close relative had severe vision loss starting in infancy, especially with nystagmus or very poor night vision—early confirmation guides surveillance and support. Testing is also helpful before family planning to understand inheritance and carrier risks. If diagnosed, results can personalize low-vision care and eligibility for emerging trials.
Diagnosis
When vision concerns show up in the first months of life—like a baby not tracking faces, constant eye wobble, or pressing on the eyes—families often seek answers quickly. Early and accurate diagnosis can help you plan ahead with confidence. The genetic diagnosis of Leber congenital amaurosis 7 typically combines a careful eye exam with specialized retinal tests and DNA analysis to confirm the exact subtype and guide care.
Parents and caregivers describe poor eye contact, light sensitivity, and rapid eye movements starting in infancy. A short review of pregnancy, birth, and family history helps narrow the possibilities.
Doctors check fixation, eye alignment, and pupil responses, and look at the front and back of the eyes. Findings can range from a normal-looking retina early on to visible retinal changes later in Leber congenital amaurosis 7.
This test measures the retina’s electrical response to light and is often severely reduced or absent in LCA. An ERG that is nearly or completely “extinguished” supports a diagnosis of Leber congenital amaurosis 7.
Providers assess how the pupils react to light, which may be weak or delayed. Abnormal pupil reflexes add supportive evidence for LCA in infants who cannot complete standard vision tests.
Stages of Leber congenital amaurosis 7
Leber congenital amaurosis 7 does not have defined progression stages. It usually shows up in infancy with severe vision problems, and while eyesight can change over time, the pattern isn’t a step-by-step stage model and can vary widely between people. Doctors look for early symptoms of Leber congenital amaurosis 7—such as poor visual response in babies, light sensitivity, or eye-wandering—and combine this with detailed eye exams. Different tests may be suggested to help confirm the diagnosis, including retinal imaging, electrical testing of the retina, and genetic testing to pinpoint the cause.
Outlook and prognosis
Looking ahead can feel daunting, but many people with Leber congenital amaurosis 7 (LCA7) grow into active, independent adults with the right adaptations at home, school, and work. This condition primarily affects vision from infancy or early childhood, often with night blindness, light sensitivity, and very reduced clarity; hearing, movement, growth, and lifespan are typically not affected. Doctors call this the prognosis—a medical word for likely outcomes. Most people with LCA7 keep some usable light perception for years, but vision often declines over time as the retina thins, and many eventually meet criteria for legal blindness.
People living with LCA7 sometimes worry about life expectancy; the good news is that LCA7 itself is not known to shorten life. The bigger day‑to‑day impact is functional: reading print, recognizing faces across a room, or navigating dim hallways can be hard, so tools like high‑contrast materials, braille or audio, mobility training, and assistive tech can be game‑changers. In medical terms, the long-term outlook is often shaped by both genetics and lifestyle. Some people experience earlier, faster vision loss, while others notice a slower change across childhood into adulthood, which is why early symptoms of Leber congenital amaurosis 7 and the pace of change can look different from one person to the next.
Here’s what research and experience suggest about the future. There is no proven cure yet, but clinical trials are exploring gene‑based therapies, and supportive care is strong: low‑vision services, school accommodations, lighting optimization, and regular eye checks help protect the remaining vision and independence. With ongoing care, many people maintain meaningful independence and stable overall health. Talk with your doctor about what your personal outlook might look like, including whether genetic testing could clarify the specific gene change and eligibility for trials.
Long-term effects
Living with Leber congenital amaurosis 7 often means working around vision challenges from early life that continue into adulthood. Long-term effects vary widely, and the pace of change can differ even within the same family. Many people recall early symptoms of Leber congenital amaurosis 7 like poor vision in infancy and trouble in dim rooms, which set the stage for what follows. Over time, daily routines may shift to rely more on touch, sound, and structured environments as vision changes.
Severe vision impairment starts early and usually remains throughout life. For some, it ranges from limited usable vision to only light perception. In Leber congenital amaurosis 7, clarity is often poor even with lenses.
Many experience gradual decline over childhood and adulthood. Some eventually lose remaining light perception. The rate of change varies from person to person.
Involuntary eye movements (nystagmus) often persist. They can make focusing and tracking objects harder. The intensity may lessen with age but rarely disappears.
Bright light and glare can feel uncomfortable. This can wash out remaining detail and make outdoor activities challenging. People with Leber congenital amaurosis 7 often prefer softer lighting.
How is it to live with Leber congenital amaurosis 7?
Living with Leber congenital amaurosis 7 often means navigating very low vision from infancy, with the world’s details dimmed or missing while sounds, touch, and routines become key guides. Daily life may involve high-contrast tools, tactile labels, screen readers, mobility training, and regular ophthalmology visits, with fatigue from concentrating harder on tasks that rely on sight. Families, classmates, and coworkers usually adjust by improving lighting and contrast, offering clear verbal descriptions, and giving extra time—support that helps independence rather than replacing it. Many find confidence grows as they build reliable strategies, use assistive technology, and connect with low-vision services and community resources.
Treatment and drugs
Treatment for Leber congenital amaurosis 7 focuses on maximizing vision, supporting development, and protecting eye health, since no approved cure currently restores the lost retinal function. Care typically includes low-vision services (special lenses, lighting, magnifiers, screen readers), orientation and mobility training, and educational support to help children and adults function safely and independently at home, school, and work. Doctors may recommend treating common eye issues that can come along with LCA7—like significant farsightedness, nystagmus, or cataracts—because improving these can make the most of remaining sight; a doctor may adjust your dose to balance benefits and side effects if medicines (for example, for eye surface comfort) are used. Protecting the eyes from bright light with sunglasses and hats, using high-contrast environments, and regular follow-up with a retinal specialist are important parts of ongoing care. Research is ongoing into gene-based and cell-based therapies for Leber congenital amaurosis 7, and clinical trials may be an option for some; ask your doctor about the best starting point for you.
Non-drug treatment
For many families, day-to-day support matters as much as future treatments for Leber congenital amaurosis 7. Non-drug treatments often lay the foundation for independence, safety, and learning at every age. These approaches won’t restore lost photoreceptor function, but they can boost remaining vision, reduce strain, and build practical skills. Early referrals help, and care usually evolves as needs change from infancy through adulthood.
Specialized eye-care teams assess how you use your vision in real life. They tailor strategies and tools to your goals at home, school, and work.
Handheld magnifiers, stand magnifiers, and telescopes can make print and signs easier to see. Electronic video magnifiers let you adjust zoom, contrast, and color.
Screen readers, text-to-speech, and voice assistants support reading, homework, and navigation on phones and computers. Braille displays and large-print settings expand access to school and work.
Training with a white cane, landmarks, and safe street-crossing techniques builds confidence. Lessons may include public transport skills and indoor wayfinding.
Your genes may have an impact on how drugs work for you
Some medicines for people with Leber congenital amaurosis 7 may work differently depending on variants in genes that affect drug processing or retinal cell pathways. Pharmacogenetic testing can sometimes guide dosing or choice, but eye-specific gene therapies target the disease gene directly.
Pharmacological treatments
For Leber congenital amaurosis 7 (LCA7), no medicine can restore or halt the underlying vision loss yet. Care focuses on easing day-to-day visual symptoms and treating specific eye findings when they show up. Drugs that target symptoms directly are called symptomatic treatments. A gene therapy exists for a different LCA type (RPE65), but not for LCA7 at this time.
These carbonic anhydrase inhibitor eye drops may reduce cystoid macular swelling if it develops in LCA7. Some people notice slightly clearer contrast; stinging or irritation can occur.
Another carbonic anhydrase inhibitor that can be tried for macular swelling related to Leber congenital amaurosis 7. It may be better tolerated than dorzolamide for some; blurred vision right after dosing is possible.
An oral carbonic anhydrase inhibitor sometimes used if eye drops don’t adequately control macular edema in LCA7. It requires monitoring for side effects like tingling, fatigue, or low potassium and is avoided with certain sulfa allergies.
Off-label, it may help ease bothersome nystagmus symptoms (eye shaking) in some older children or adults with Leber congenital amaurosis 7. Drowsiness and dizziness can occur, so dosing is adjusted carefully.
Genetic influences
In most cases, Leber congenital amaurosis 7 stems from a change in a gene called CRX, which helps the light‑sensing cells in the eye form and work properly. Even with the same gene change, people can have different degrees of vision loss and different ages when symptoms show up. LCA7 often follows a dominant inheritance pattern—one altered copy of CRX is enough—so a parent living with LCA7 has a 1 in 2 (50%) chance of passing it to each child. In other families, the CRX change appears for the first time in a child (a new, or de novo, variant), so there may be no earlier family history. Genetic testing for Leber congenital amaurosis 7 can confirm the genetic cause, pinpoint the exact variant, and inform care, clinical trials, and who else in the family may benefit from screening. If you’re exploring the genetic causes of Leber congenital amaurosis 7, meeting with a genetics specialist can help you understand results and plan next steps.
Is Leber congenital amaurosis 7 genetic?
Genetics are central to Leber congenital amaurosis 7; it’s caused by inherited changes in the gene usually passed in an autosomal recessive pattern. Variants influence severity, age at diagnosis, and response to emerging gene-specific therapies. Genetic testing guides care and family planning.
Pharmacogenetics—how genetics influence drug effects
Because Leber congenital amaurosis 7 (LCA7) is driven by changes in the CRX gene, treatment choices depend heavily on confirming the exact variant. Doctors can use your genetic information to guide eligibility for gene‑directed therapies and clinical trials. Unlike the approved gene therapy for RPE65‑related LCA, there is currently no approved drug or gene therapy for CRX‑related LCA7; research is exploring approaches that either dampen the harmful gene copy or carefully restore CRX function. Your specific mutation, the amount of healthy retina left, and age often shape whether a study is a good fit and how a treatment might be delivered. Traditional drug‑metabolism markers don’t currently guide everyday medicines for LCA7, but knowing the genotype helps set expectations and focuses care on supportive options while keeping an eye on emerging trials. High‑dose vitamin A and similar supplements haven’t been shown to help LCA7 and may carry risks, so clinicians usually discourage megadoses and emphasize low‑vision care and protection while monitoring for gene‑specific opportunities.
Interactions with other conditions
Living with severe vision loss from childhood can make other eye problems feel bigger; for example, frequent eye rubbing linked to Leber congenital amaurosis 7 may raise the chance of keratoconus (a cone-shaped cornea) that further blurs vision. While Leber congenital amaurosis 7 mainly affects the retina and is usually limited to the eyes, care teams still watch for signs that suggest something more widespread, such as unusual developmental delays or hearing changes, so nothing is missed. Some conditions share “underlying mechanisms,” such as different changes in the same gene leading to related retinal diseases like cone‑rod dystrophy or macular dystrophy in the same family. Cataracts and significant focusing problems can develop and add another layer to the vision challenges, and if someone also has diabetes later in life, reviewing the retina for diabetic changes can be more complex but is still possible with specialist care. It’s also wise to review supplements and medicines with your clinician, since high‑dose vitamin A is generally not recommended in inherited retinal diseases unless a specialist advises it. When another health issue is present, early symptoms of Leber congenital amaurosis 7—like light sensitivity or constant eye searching—can be harder to spot, so coordinated follow‑up helps keep the overall picture clear.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described babies who didn’t track faces, blink to bright light, or reach for toys, long before doctors had a name for it. Families noticed that some children shook or rubbed their eyes constantly and preferred dim rooms. In many places, relatives quietly adjusted life at home—moving furniture, adding touch cues—while wondering why vision didn’t improve with age.
From early theories to modern research, the story of Leber congenital amaurosis 7 has moved from careful bedside notes to pinpointing a single gene. Early case reports grouped many forms of severe infant-onset vision loss together under “congenital amaurosis.” Doctors recognized the shared features—markedly reduced vision in the first months of life, very low responses on vision tests—but couldn’t tell one subtype from another. As electrical testing of the retina became common, patterns emerged, yet the cause remained unclear.
Advances in genetics changed the pace. In the late 20th and early 21st centuries, teams comparing DNA in affected families identified several genes tied to Leber congenital amaurosis. One of these was LCA7, linked to changes in a gene that helps the light-sensing cells of the retina work properly. This step split what was once a single label into distinct genetic subtypes, each with its own course and prospects for future treatment.
With each decade, testing became more precise. What used to require large family studies could be confirmed with a blood or saliva test. Clinicians began to recognize that Leber congenital amaurosis 7 often presents in infancy with poor visual responsiveness, nystagmus (eye shaking), and very reduced retinal signals, while the appearance of the retina can range from near normal early on to later thinning. This clarified why some toddlers seemed stable for a time and then gradually lost more vision.
In recent decades, knowledge has built on a long tradition of observation. Genetic registries and natural history studies have mapped how vision changes over years, guiding care and research. As gene-based therapies entered clinical trials for other retinal conditions, interest grew in whether similar approaches might one day help people with Leber congenital amaurosis 7. Not every early description was complete, yet together they built the foundation of today’s knowledge, giving families clearer answers about cause, inheritance, and supportive options while research continues.